Cargando…

Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection

BACKGROUND: Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Moga, Silvia, Teodorescu, Andreea, Ifteni, Petru, Petric, Paula-Simina, Miron, Ana-Aliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081886/
https://www.ncbi.nlm.nih.gov/pubmed/35547265
http://dx.doi.org/10.2147/NDT.S361405
_version_ 1784703091775373312
author Moga, Silvia
Teodorescu, Andreea
Ifteni, Petru
Petric, Paula-Simina
Miron, Ana-Aliana
author_facet Moga, Silvia
Teodorescu, Andreea
Ifteni, Petru
Petric, Paula-Simina
Miron, Ana-Aliana
author_sort Moga, Silvia
collection PubMed
description BACKGROUND: Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed to provide a study on the association between neutropenia and clozapine in patients with schizophrenia and COVID-19. AIM: To assess the neutrophil count in patients with schizophrenia treated with clozapine and infected with COVID-19. METHODS: The study patients with schizophrenia, according to DSM-5, admitted to the Clinical Hospital of Psychiatry and Neurology Brasov, Romania, between April 2020 and October 2021. The inclusion criteria included positive RT-PCR (real-time PCR) test for COVID-19 and treatment with clozapine. We assessed three values of ANC (absolute neutrophil count): before COVID-19 infection (last ANC obtained at mandatory check), during infection and 1 month after resolution (first negative PCR test). RESULTS: Of the 105 cases, 95 did not have neutropenia. Fifty-nine patients were males (62.1%), mean age was 43.5 years (SD = 12.1) with an average of clozapine treatment of 52.4 months (SD = 11.9). At baseline, they had a small reduction in the ANC mean value (4.41 × 109/l; SD = 2.22) which did not constitute a statistically significant decline from the prior to COVID-19 mean value of 4.66 × 109/l (SD = 2.34; p = 0.45). Values were also normal in the first month after negative PCR testing (4.45 × 109/l; SD = 2.35; p = 0.91). A total of 10 patients (9.5%) had neutropenia. The age, dose of clozapine and duration of treatment were not statistically different compared to the group without neutropenia. CONCLUSION: Psychiatrists and other health professionals should keep in mind that neutrophil count may decrease during COVID-19 infection in patients taking clozapine and in some cases, neutropenia may even occur. We assumed that neutropenia could be caused by COVID-19 and clozapine interaction.
format Online
Article
Text
id pubmed-9081886
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-90818862022-05-10 Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection Moga, Silvia Teodorescu, Andreea Ifteni, Petru Petric, Paula-Simina Miron, Ana-Aliana Neuropsychiatr Dis Treat Original Research BACKGROUND: Clozapine (CLZ) is used for treatment-resistant schizophrenia (TRS). Adverse reactions to clozapine include neutropenia. In March 2020, WHO declared the COVID-19 pandemic and after, psychiatrists raised concerns regarding continuation of clozapine, due to multiple restrictions. We aimed to provide a study on the association between neutropenia and clozapine in patients with schizophrenia and COVID-19. AIM: To assess the neutrophil count in patients with schizophrenia treated with clozapine and infected with COVID-19. METHODS: The study patients with schizophrenia, according to DSM-5, admitted to the Clinical Hospital of Psychiatry and Neurology Brasov, Romania, between April 2020 and October 2021. The inclusion criteria included positive RT-PCR (real-time PCR) test for COVID-19 and treatment with clozapine. We assessed three values of ANC (absolute neutrophil count): before COVID-19 infection (last ANC obtained at mandatory check), during infection and 1 month after resolution (first negative PCR test). RESULTS: Of the 105 cases, 95 did not have neutropenia. Fifty-nine patients were males (62.1%), mean age was 43.5 years (SD = 12.1) with an average of clozapine treatment of 52.4 months (SD = 11.9). At baseline, they had a small reduction in the ANC mean value (4.41 × 109/l; SD = 2.22) which did not constitute a statistically significant decline from the prior to COVID-19 mean value of 4.66 × 109/l (SD = 2.34; p = 0.45). Values were also normal in the first month after negative PCR testing (4.45 × 109/l; SD = 2.35; p = 0.91). A total of 10 patients (9.5%) had neutropenia. The age, dose of clozapine and duration of treatment were not statistically different compared to the group without neutropenia. CONCLUSION: Psychiatrists and other health professionals should keep in mind that neutrophil count may decrease during COVID-19 infection in patients taking clozapine and in some cases, neutropenia may even occur. We assumed that neutropenia could be caused by COVID-19 and clozapine interaction. Dove 2022-05-04 /pmc/articles/PMC9081886/ /pubmed/35547265 http://dx.doi.org/10.2147/NDT.S361405 Text en © 2022 Moga et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Moga, Silvia
Teodorescu, Andreea
Ifteni, Petru
Petric, Paula-Simina
Miron, Ana-Aliana
Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
title Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
title_full Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
title_fullStr Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
title_full_unstemmed Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
title_short Clozapine and Neutropenia in Patients with Schizophrenia and SARS-CoV-2 Infection
title_sort clozapine and neutropenia in patients with schizophrenia and sars-cov-2 infection
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081886/
https://www.ncbi.nlm.nih.gov/pubmed/35547265
http://dx.doi.org/10.2147/NDT.S361405
work_keys_str_mv AT mogasilvia clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection
AT teodorescuandreea clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection
AT iftenipetru clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection
AT petricpaulasimina clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection
AT mironanaaliana clozapineandneutropeniainpatientswithschizophreniaandsarscov2infection